Drug details:
Molecular formula: C₁₉H₁₇F₂N₃O₄S

Standard name: N-(2,4-difluorophenyl)-4-[(3-ethoxy-4-hydroxyphenyl)methyl]-5-oxo-1,3,4-thiadiazine-2-carboxamide

Synonyms:

CL-55 N-(2,4-difluorophenyl)-4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4h-[1,3,4]-thiadiazine-2-carboxamide

Curated SMILES: CCOC1=CC(CN2N=C(C(=O)NC3=CC=C(F)C=C3F)SCC2=O)=CC=C1O

Evidence for compound's anti-virulence activity:

Acinetobacter
Related VFcategory: Biofilm
Target: Not determined
Drug effect: An inhibitor of a significant virulence factor that is key for septic infection, as well as an inhibitor of biofilm formation and bacterial interaction with cells.
Max phase: Preclinical (in vivo)
Publication:
Bondareva NE, et al., 2022. Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in mice. J Antibiot (Tokyo) 75(3):155-163.

Chlamydia
Related VF: TTSS (Type III secretion system)
Target: Not determined
Drug effect: An inhibition of the translocation of the TTS effectors IncG and IncA during the early and middle phase, respectively, and a bacterial detachment from the inclusion membrane during the late stage concomitant with an inhibition of terminal differentiation from RBs to infectious EBs.
Max phase: Preclinical (in vivo)
Publications:
Zigangirova NA, et al., 2012. Development of Chlamydial Type III Secretion System Inhibitors for Suppression of Acute and Chronic Forms of Chlamydial Infection. Acta Naturae 4(2):87-97.
Koroleva EA, et al., 2015. Small molecule inhibitor of type three secretion suppresses acute and chronic Chlamydia trachomatis infection in a novel urogenital Chlamydia model. Biomed Res Int 2015:484853.
Zigangirova NA, et al., 2016. A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones inhibits intracellular growth and persistence of Chlamydia trachomatis. J Med Microbiol 65(1):91-98.

Klebsiella
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Suppresses the formation of biofilms.
Max phase: Preclinical (in vitro)
Publication:
Tsarenko SV, et al., 2023. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia. J Antibiot (Tokyo) 76(7):397-405.

Pseudomonas
Related VF: TTSS (Type III secretion system)
Target: Not determined
Drug effect: Inhibits the secretion of ExoT and ExoY, reduces bacteria cytotoxicity and increases bacteria internalization.
Max phase: Preclinical (in vivo)
Publication:
Sheremet AB, et al., 2018. Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice. Biomed Res Int 2018:5810767.

Salmonella
Related VF: TTSS (SPI-1 encode); TTSS (SPI-2 encode)
Target: Not determined
Drug effect: Inhibits SPI-1 effector proteins secretion and replication Salmonella induced by SPI-2.
Max phase: Phase II trial
Publications:
Nesterenko LN, et al., 2016. A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo. J Antibiot (Tokyo) 69(6):422-7.
Zigangirova NA, et al., 2021. Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice. J Antibiot (Tokyo) 74(4):244-254.